Hepatic Arterial Embolization for the Treatment of Metastatic Neuroendocrine Tumors

Table 1

Outcomes of hepatic arterial embolization in large published case series.

Author	Type of embolization	No. of patients/No. of embolization procedures	Survival	Comments
Bloomston et al. [36]	TACE	122/156	PFS: 10 months; OS: 33 months; 5-yr survival: 28%	Symptom improvement associated with increase in OS
Swärd et al. [33]	TAE	107/213	OS: 56 months	Increased survival with reduction in 5-HIAA; reduced survival with increased AST or chromogranin A
Pitt et al. [28]	TACE and TAE	100/229	TACE OS: 25.5; TAE OS: 25.7; TACE 5-yr survival: 19%; TAE 5-yr survival: 13%	OS and 5-yr survival not statistically different between TAE and TACE; resection of primary tumor increased OS
Kamat et al. [23]	TACE and TAE	60/123	OS: 18 months; PFS: 9 months	Patients had greater than 75% hepatic tumor burden; symptom; improvement seen in 65%; major complication rate of 29%
Varker et al. [37]	Repeat TACE	27/54	OS: 28 months; PFS: 5 months	Repeat TACE associated with similar OS and PFS, and lower complication rates compared to single TACE